Co-founder and Chief Executive Officer of Kannalife Sciences, Inc. Responsible for the creation and execution of the Company’s business model, the licensing of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” from the NIH, and co-inventor of the patent estate currently held by Kannalife Sciences, Inc. Responsible for raising approximately $10 million in debt, equity and grant funding for Kannalife Sciences, Inc. since its inception. In 2010, created the hypothesis and groundwork for the proposed research for the use of cannabinoid based therapeutics for the treatment of neuroinflammatory, neurodegenerative and oxidative stress related disorders. Co-inventor on the following patent grants: US 9,611,213 B2 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy”; and US 10,004,722 “Method for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediated Stress and Oxidative Stress with Novel Functionalized 1,3- Benzene Diols”. Additional jurisdictions include: Europe (twelve countries), Japan, India, China, Australia, Canada, Brazil, and Russia. Published Works: Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability (2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834656/ Pharmacological Comparisons Between Cannabidiol and KLS-13019 (2018) https://pubmed.ncbi.nlm.nih.gov/30109468/